Reduction in Proportion of Senescent CD8+ T Lymphocytes During Chemotherapy of Children with Acute Lymphoblastic Leukemia

Rutkauskaitė, Vilma; Ragelienė, Lina; Matuzeviciene, Reda; Sinkevič, Katažina; Mauricas, Mykolas; Characiejus, Dainius

doi:10.21873/anticanres.11213

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study exploring the immunomodulatory effects of chemotherapy in pediatric ALL observed a transient decrease in most T lymphocyte subsets during chemotherapy, which was restored by days 78 and 85. However, senescent CD3+CD8+CD57+ lymphocytes did not return to pretreatment levels ( 144 ).…”

Section: Tumor Immune Microenvironment In Bcp-allmentioning

confidence: 99%

Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics

Poveda-Garavito,

Combita

2024

Front. Immunol.

View full text Add to dashboard Cite

The bone marrow (BM) niche is a microenvironment where both immune and non-immune cells functionally interact with hematopoietic stem cells (HSC) and more differentiated progenitors, contributing to the regulation of hematopoiesis. It is regulated by various signaling molecules such as cytokines, chemokines, and adhesion molecules in its microenvironment. However, despite the strict regulation of BM signals to maintain their steady state, accumulating evidence in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) indicates that leukemic cells can disrupt the physiological hematopoietic niche in the BM, creating a new leukemia-supportive microenvironment. This environment favors immunological evasion mechanisms and the interaction of these cells with the development and progression of BCP-ALL. With a growing understanding of the tumor immune microenvironment (TIME) in the development and progression of BCP-ALL, current strategies focused on “re-editing” TIME to promote antitumor immunity have been developed. In this review, we summarize how TIME cells are disrupted by the presence of leukemic cells, evading immunosurveillance mechanisms in the BCP-ALL model. We also explore the crosstalk between TIME and leukemic cells that leads to treatment resistance, along with the most promising immuno-therapy strategies. Understanding and further research into the role of the BM microenvironment in leukemia progression and relapse are crucial for developing more effective treatments and reducing patient mortality.

show abstract

Section: Tumor Immune Microenvironment In Bcp-allmentioning

confidence: 99%